This contradicts what was observed by Zhang et al. [59], who used APR-246 in combination with dendritic cell-based vaccination against p53 in a methylcholanthrene-induced primary murine tumor model without observing a significant effect of the combined therapy in reducing tumor-free survival in vivo. This evidence concerns the gene TP53 and neoplasm.